immo!nvest – Die Plattform für Standorte und Immobilien

Tag: Pharmaindustrie

  • Foundation stone laid for new company building in Grabs

    Foundation stone laid for new company building in Grabs

    Frauenfeld-based HRS will be the total contractor for the construction of the new Körber Business Area Pharma building in Grabs. According to a press release, the foundation stone was laid on 13 February.

    In addition to the existing building at the site, a basement, two production floors and two office floors will be built on a vacant site. A total of 7500 square metres of production space and 5000 square metres of office space will then be created in the new building. The building itself will fulfil current sustainability and energy efficiency requirements. In addition to its own photovoltaic system on the roof, extensive charging facilities for electric cars will also be provided, according to the press release.

    The new building, which is scheduled for completion in 2027, will bring together all the resources of Körber’s Business Area Pharma.

    “The new building plays a central role in our planned growth, which is centred around our customers and, of course, our employees,” said Christoph Hammer, CEO Packaging of the Körber Business Area Pharma in Grabs, in the press release. “In addition to our spatial capacities, we are also growing our team. More than 360 colleagues are already working on the development and production of our technologies at the site. By the end of this year, this figure is set to rise to more than 390. We are creating a state-of-the-art working environment for them.”

  • Vaud economy between recovery and uncertainty

    Vaud economy between recovery and uncertainty

    Global economic tensions have increased in recent months. The OECD and the Swiss State Secretariat for Economic Affairs (SECO) point to risks, particularly from the new US administration and the unclear relations between Switzerland and the EU. While the US economy is growing more strongly than expected, the European economy remains weakened by structural challenges. The strong Swiss franc is slowing down export-orientated sectors, while domestic demand remains a stable pillar of the economy.

    Construction industry benefits from interest rate cuts
    The Swiss National Bank (SNB) has eased its monetary policy and lowered the key interest rate from 1.75% to 0.5%. This measure is creating a favourable investment climate, particularly in the construction industry, which is benefiting from falling financing costs. Forecasts for Switzerland as a whole predict growth of 1.5% this year and an acceleration to 1.7% next year.

    Sector development mixed picture
    While the industrial economy continues to be challenged, other sectors are showing mixed developments. The retail and hospitality sectors are struggling with a weak business climate, while the service sector is showing positive momentum. Particularly strong growth is forecast for the chemical and pharmaceutical industries, business services and the financial sector. The machinery and watchmaking industry could also benefit from the economic recovery in the medium term.

    Stabilisation with uncertainties
    The Vaud economy is looking forward to a year of opportunities, but also challenges. While key sectors are likely to benefit from a sustained recovery, geopolitical and currency policy uncertainties remain risk factors. The decisive factors will be how international trade relations and the domestic economy develop and the extent to which companies are able to react flexibly to changes.

  • GETEC takes over Rhine Valley Life Science Park from Novartis

    GETEC takes over Rhine Valley Life Science Park from Novartis

    The pharmaceutical group Novartis is handing over the further development of the Rhine Valley Life Science Park in Stein to the energy service provider and industrial park operator GETEC, based in Muttenz BL. According to a Novartis media release, the aim is to maximise the economic potential of the park and develop it professionally. Financial details of this transaction were not disclosed. The transfer of all assets is expected to be completed by the end of 2023.

    Novartis will retain the site as its largest tenant and will continue to manufacture medicines and therapies there. The company operates a manufacturing plant in Stein for solid dosage forms and drugs for injection, cell and gene therapies, as well as a milling and mixing centre for chemical manufacturing.

    “After a detailed analysis, Novartis has come to the conclusion that transferring the management of the Rhine Valley Life Science Park to a professional industrial park operator can better maximise and develop the economic potential of the site and facilitate the settlement of new companies,” Steffen Lang, President Operations and member of the Novartis Executive Board, is quoted as saying. In return, Novartis can better focus on its core business.

    GETEC belongs to the GETEC Group, which is based in Magdeburg in the German state of Saxony-Anhalt. The group is also active in the Netherlands and Italy. In Switzerland, it also operates the 50-hectare industrial site in Muttenz.

    The Canton of Aargau’s location promotion department welcomes the change of ownership in the Sisslerfeld area, a strategic development focus for the canton: “The Sisslerfeld has great potential for high value-added businesses and thus for significantly more jobs,” says the head of location promotion, Verena Rohrer. “The transfer to GETEC enables us to jointly attract further, innovative companies to the greater Sisslerfeld area that can cooperate with each other.”